<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2821">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327401</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 30227020.5.1001.0008</org_study_id>
    <nct_id>NCT04327401</nct_id>
  </id_info>
  <brief_title>COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III</brief_title>
  <acronym>CoDEX</acronym>
  <official_title>COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Sirio-Libanes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brazilian Research In Intensive Care Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Sirio-Libanes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized
      infectious disease of the respiratory tract. Most cases are mild or asymptomatic. However,
      around 5% of all patients develop Acute Respiratory Distress Syndrome (ARDS), which is the
      leading mortality cause in these patients. Corticosteroids have been tested in deferent
      scenarios of ARDS, including viral pneumonia, and the early use of dexamethasone is safe and
      appears to reduce the duration of mechanical ventilation in ARDS patients. Nevertheless, no
      large, randomized, controlled trial was performed evaluating the role of corticosteroids in
      patients with ARDS due SARS-CoV2 virus. Therefore, the present study will evaluate the
      effectiveness of dexamethasone compared to control (no corticosteroids) in patients with
      moderate and severe ARDS due to SARS-CoV2 virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized
      infectious disease of the respiratory tract, and its outbreak deemed a pandemic in early
      March 2020. Estimates show around 5% of all patients develop Acute Respiratory Distress
      Syndrome (ARDS), which due to its severity, consumes most Intensive Care Units (ICU)
      resources and is the leading mortality cause in this population. Given its burden, therapies
      that reduce the duration of mechanical ventilation or decrease the morbimortality are needed.
      Studies indicate that inflammation and cytokine storm might be involved in the
      pathophysiological pathway to ARDS in these patients. Corticosteroids have been tested in
      deferent scenarios of ARDS, including viral pneumonia, and the early use of dexamethasone is
      safe and appears to reduce the duration of mechanical ventilation in ARDS patients. A recent
      small retrospective study evaluating the role of corticosteroids found no association between
      corticosteroids and hospital length of stay, virus clearance, and symptoms' duration.
      However, the retrospective nature of data, small sample size (31 patients), and no protocol
      for corticosteroids administration undermine its results. Therefore, the present study will
      evaluate the effectiveness of dexamethasone compared to control (no corticosteroids) in
      ventilator-free days at 28 days in patients with moderate and severe ARDS due to SARS-CoV2
      virus in Brazil.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial
    results, which was accepted by the CoDEX Steering Committee.
  </why_stopped>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Actual">July 22, 2020</completion_date>
  <primary_completion_date type="Actual">July 22, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dexamethasone. After randomization, dexamethasone 20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days + standard treatment (according to the treatment protocol for 2019-nCoV infection).
Standard treatment (according to the treatment protocol for 2019-nCoV infection).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Ventilator-free days, defined as alive and free from mechanical ventilation, at 28 days after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the clinical status</measure>
    <time_frame>15 days after randomization</time_frame>
    <description>Evaluation of the clinical status of patients on the 15th day after randomization defined by the 6-point Ordinal Scale, this scale ranges from 1 (Not hospitalized) to 6 (Death) with higher scores meaning worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>All-cause mortality rates at 28 days after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation duration</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Number of days of mechanical ventilation from randomization to day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>Score at 48 hours, 72 hours and 7 days after randomization</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) Score 48 hours, 72 hours and 7 days after randomization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intensive Care Unit free days</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Intensive Care Unit free days, defined as alive and discharged from the intensive care unit, at 28 days after randomization.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone. After randomization, dexamethasone [20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days] + standard treatment (according to the treatment protocol for 2019-nCoV infection).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment (according to the treatment protocol for 2019-nCoV infection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone administration for 10 consecutive days after randomization.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>Dexasone</other_name>
    <other_name>Diodex</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Maxidex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable or confirmed infection by SARS-CoV2

          -  Intubated and mechanically ventilated

          -  Moderate/severe ARDS defined by the Berlin criteria (PaO2/FiO2 ≤200mmHg with PEEP
             ≥5cmH20)

          -  Onset of moderate/severe ARDS in less than 48 hours before randomization

        Exclusion Criteria:

          -  Pregnancy or active lactation

          -  Known history of dexamethasone allergy

          -  Daily use of corticosteroids in the past 15 days

          -  Clinical indication for corticosteroids use for other diseases (i.e refractory septic
             shock)

          -  Patients who did use corticosteroids during hospital stay for periods equal or greater
             than two days

          -  Use of immunosuppressive drugs

          -  Cytotoxic chemotherapy in the past 21 days

          -  Neutropenia due to hematological or solid malignancies with bone marrow invasion

          -  Patient expected to die in the next 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano Cesar Pontes Azevedo, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Teaching Director of Teaching &amp; Research Institute Sírio-Libanês Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ana Nery</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Distrito Federal</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Social Rural de Colatina</name>
      <address>
        <city>Colatina</city>
        <state>Esoírito Santo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz AS</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maternidade E Pronto Socorro Santa Lucia Ltda</name>
      <address>
        <city>Poços De Caldas</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eurolatino Natal Pesquisas Médicas Ltda</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maestri E Kormann Consultoria Medico-Cientifica</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Literaria e Caritativa Santo Agostinho</name>
      <address>
        <city>Criciúma</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Pio XII</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Votuporanga</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associacao Beneficente Siria</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prevent Senior Private Operadora de Saude Ltda</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Real e Benemérita Associação Portuguesa de Beneficência/SP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Secretaria de Saúde do Estado de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sírio-Libanês</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Sirio-Libanes</investigator_affiliation>
    <investigator_full_name>Luciano Cesar Pontes de Azevedo</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV2 virus</keyword>
  <keyword>2019-nCOV</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>ARDS</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT04327401/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

